PremiumCompany AnnouncementsPerspective Therapeutics Reports Q1 2025 Results and Updates Buy Rating for Perspective Therapeutics: Promising Advancements in Targeted Radioligand Therapy Perspective Therapeutics announces first patient dosed with PSV359 PremiumThe FlyPerspective Therapeutics price target lowered to $10 from $21 at Truist Positive Outlook for Perspective Therapeutics Despite Wider Net Loss, Supported by Strong Cash Position and Upcoming Catalysts Perspective Therapeutics management to meet with Oppenheimer PremiumRatingsPromising Clinical Developments and Unique Mechanism Drive Buy Rating for Perspective Therapeutics Promising Developments and Strategic Trial Design Justify Buy Rating for Perspective Therapeutics Perspective Therapeutics says first patient dosed in Phase 1/2a trial of VMT01 
